EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate

Pilar Pizcueta, Cristina Vergara, Marco Emanuele, Anna Vilalta iD, Laura Rodríguez-Pascau iD, Marc Martinell

International Journal of Molecular Sciences · 06.02.2023 · 24 (4) · 3201

DOI: 10.3390/ijms24043201 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.02.2023. Verfasst von Pilar Pizcueta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Minoryx Therapeutics SL, 08302 Barcelona, Spain. Hauptthemen laut MEDLINE: Central Nervous System Diseases, Neurodegenerative Diseases. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Region Wallonne, Région Wallonne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increasing evidence suggests that the peroxisome proliferator-activated receptor γ (PPARγ), a member of the nuclear receptor superfamily, plays an important role in physiological processes in the central nervous system (CNS) and is involved in cellular metabolism and repair. Cellular damage caused by acute brain injury and long-term neurodegenerative disorders is associated with alterations of these metabolic processes leading to mitochondrial dysfunction, oxidative stress, and neuroinflammation. PPARγ agonists have demonstrated the potential to be effective treatments for CNS diseases in preclinical models, but to date, most drugs have failed to show efficacy in clinical trials of neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s disease. The most likely explanation for this lack of efficacy is the insufficient brain exposure of these PPARγ agonists. Leriglitazone is a novel, blood–brain barrier (BBB)-penetrant PPARγ agonist that is being developed to treat CNS diseases. Here, we review the main roles of PPARγ in physiology and pathophysiology in the CNS, describe the mechanism of action of PPARγ agonists, and discuss the evidence supporting the use of leriglitazone to treat CNS diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System DiseasesNeurodegenerative DiseasesHumansNeuroinflammatory DiseasesPPAR gammaThiazolidinediones

Stichwörter der Autor:innen

PPARγ agonistclinical trialsleriglitazonemitochondrianeurodegenerative diseaseneuroinflammation

Substanzen

PPAR gammaleriglitazoneThiazolidinedionesPPARG protein, human

Autor:innen und Institutionen

  • Minoryx Therapeutics SL, 08302 Barcelona, Spain.
  • Minoryx Therapeutics BE, Gosselies, 6041 Charleroi, Belgium.

ORCID-Profile: Anna Vilalta, Laura Rodríguez-Pascau

Förderung

  • Region Wallonne
  • Région Wallonne

Zitieren

APA

Pizcueta, P., Vergara, C., Emanuele, M., Vilalta, A., Rodríguez-Pascau, L., & Martinell, M. (2023). Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. International Journal of Molecular Sciences, 24(4), 3201. https://doi.org/10.3390/ijms24043201

Vancouver

Pizcueta P, Vergara C, Emanuele M, Vilalta A, Rodríguez-Pascau L, Martinell M. Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. International Journal of Molecular Sciences. 2023;24(4):3201. doi:10.3390/ijms24043201

BibTeX
@article{Pizcueta2023,
  author = {Pizcueta, Pilar and Vergara, Cristina and Emanuele, Marco and Vilalta, Anna and Rodríguez-Pascau, Laura and Martinell, Marc},
  title = {Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {4},
  pages = {3201},
  doi = {10.3390/ijms24043201}
}
Kostenlos starten →